Gilead Blockbuster Hepatitis C Drug Patent Infringement Ruling Overturned

A federal judge recently overturned a jury verdict that required Gilead Sciences to pay $2.54 billion over charges that its blockbuster hepatitis C virus (HCV) drugs sofosbuvir (Sovaldi) and ledipasvir/sofosbuvir (Harvoni) infringed on patents held by Merck & Co, according to Reuters.

http://bit.ly/2Fjy18W